Literature DB >> 12372344

Constitutive and inducible expression of the epithelial antigen MUC1 (CD227) in human T cells.

Andrea Fattorossi1, Alessandra Battaglia, Paolo Malinconico, Andrea Stoler, Leila Andreocci, Dino Parente, Annamaria Coscarella, Nicola Maggiano, Alessandro Perillo, Luca Pierelli, Giovanni Scambia.   

Abstract

MUC1 (CD227) is a large glycoprotein normally produced by epithelial tissue and expressed aberrantly in carcinomas. Here we show that resting human T cells express basal levels of MUC1 mRNA and protein forms with molecular masses of approximately 150 and approximately 250 intracellularly, but lack surface expression. Mitogenic stimulation induces the appearance of new MUC1 mRNA and >300-kDa MUC1 forms. Concomitantly, MUC1 is translocated to the outer cell membrane and its density is continuously modulated according to the cycling status. Inhibitors of mRNA and protein synthesis and of Golgi-dependent protein transport prevent MUC1 induction. Ligation of surface MUC1 has no effect on T-cell proliferation. Also, altering the overall protein structure by preventing glycosylation has no effect. Sizable amounts of >300-kDa glycosylated MUC1 forms are shed by proliferating T cells. This soluble MUC1 does not appear to influence T-cell response, and we found no evidence for MUC1 binding sites on T cells or for transfer of the protein on cell-cell contact. We therefore suggest that MUC1 fulfills the criteria for an early T-cell activation marker but its function remains to be determined. Finally, although we found that cancer- and T cell-associated MUC1 expose common protein core and sialylated epitopes, there is a peptide region, accessible in carcinomas due to an aberrant glycosylation, that is stably not accessible in T cells with potential implications for cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12372344     DOI: 10.1006/excr.2002.5591

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  10 in total

1.  Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment.

Authors:  Andrea Fattorossi; Alessandra Battaglia; Alexia Buzzonetti; Francesca Ciaraffa; Giovanni Scambia; Amelia Evoli
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

2.  Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity.

Authors:  Kirstine Lavrsen; Caroline B Madsen; Morten G Rasch; Anders Woetmann; Niels Ødum; Ulla Mandel; Henrik Clausen; Anders E Pedersen; Hans H Wandall
Journal:  Glycoconj J       Date:  2012-08-10       Impact factor: 2.916

Review 3.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

4.  Paraneoplastic diseases associated with thymoma.

Authors:  Amelia Evoli; Giacomo Maria Minicuci; Roberta Vitaliani; Alessandra Battaglia; Giacomo Della Marca; Libero Lauriola; Andrea Fattorossi
Journal:  J Neurol       Date:  2007-02-26       Impact factor: 4.849

5.  Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer.

Authors:  Alessandra Battaglia; Alexia Buzzonetti; Giovanni Monego; Laura Peri; Gabriella Ferrandina; Francesco Fanfani; Giovanni Scambia; Andrea Fattorossi
Journal:  Immunology       Date:  2007-11-20       Impact factor: 7.397

6.  Lymphocyte populations in human lymph nodes. Alterations in CD4+ CD25+ T regulatory cell phenotype and T-cell receptor Vbeta repertoire.

Authors:  Alessandra Battaglia; Gabriella Ferrandina; Alessia Buzzonetti; Paolo Malinconico; Francesco Legge; Vanda Salutari; Giovanni Scambia; Andrea Fattorossi
Journal:  Immunology       Date:  2003-11       Impact factor: 7.397

Review 7.  The adenocarcinoma cell surface mucin receptor for alpha-fetoprotein: is the same receptor present on circulating monocytes and macrophages? A commentary.

Authors:  G J Mizejewski
Journal:  Tumour Biol       Date:  2014-06-12

8.  Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms.

Authors:  Lixin Zhang; Anda Vlad; Christine Milcarek; Olivera J Finn
Journal:  Cancer Immunol Immunother       Date:  2012-09-02       Impact factor: 6.968

Review 9.  Mechanisms of antitumor and immune-enhancing activities of MUC1/sec, a secreted form of mucin-1.

Authors:  Dan Ilkovitch; Roberto Carrio; Diana M Lopez
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

10.  Prognostic significance of membrane-associated mucins 1 and 4 in gastric adenocarcinoma.

Authors:  Ilseon Hwang; Yu Na Kang; Jin Young Kim; Young Rok DO; Hong Suk Song; Keon Uk Park
Journal:  Exp Ther Med       Date:  2012-06-01       Impact factor: 2.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.